Lactoferrin supplement for diabetic kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether taking a lactoferrin supplement can help people with type 2 diabetes and chronic kidney disease (stage 3 or 4) by reducing protein in their urine, which is a sign of kidney damage. It may offer a new way to slow the progression of kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have type 2 diabetes and chronic kidney disease at stage 3 or 4, meaning your kidneys are moderately to severely reduced in function.
- You have increased levels of a protein called albumin in your urine, which indicates kidney damage.
- You have been on a stable treatment plan for your diabetes and kidney disease for at least 3 months.
- You are not pregnant or breastfeeding and have a life expectancy of more than one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LC-Z300-01 to see if it can reduce protein in the urine of people with type 2 diabetes and diabetic kidney disease. If you have diabetic kidney disease and are already on standard kidney-protective medications, this trial may offer a potential new treatment option.
This trial tests if a drug called formoterol (usually used for asthma) can help protect the kidneys in people with type 2 diabetes and early-to-moderate kidney disease. It may offer a new way to slow kidney damage.
This study tests a once-daily pill called finerenone to see if it can reduce protein in the urine (a sign of kidney damage) in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and slow down disease progression.
This study tests a four-drug combination to see if it can better protect the kidneys in people with type 2 diabetes and kidney disease. If you qualify, you may receive this combination therapy and be monitored for 6 months.
This trial is testing a medication called finerenone to see how well it helps people with type 2 diabetes who also have chronic kidney disease. Researchers are looking at how the drug affects kidney function and related health factors.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
Hear when a new Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.